权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Continuation of The Collaborative Islet Transplantation Registry (CITR)

协作胰岛移植登记处 (CITR) 的延续

基本信息

批准号：
10704577
负责人：
Elizabeth Holly Payne
金额：
$ 70.37万
依托单位：
THE EMMES COMPANY, LLC
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-09-15 至 2027-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10704577
关键词：
Address Allogenic Autologous Biometry Case Report Form Cell physiology Clinical Clinical Treatment Collaborations Collection Communication Communities Complex Data Data Collection Data Reporting Development Diabetes Mellitus Ensure Funding Goals Health Human Hypoglycemia Insulin-Dependent Diabetes Mellitus International Islet Cell Islets of Langerhans Islets of Langerhans Transplantation Journals Knowledge Lead Leadership Manuscripts Methods National Institute of Diabetes and Digestive and Kidney Diseases Outcome Pancreatectomy Peer Review Persons Positioning Attribute Publications Refractory Registries Research Personnel Resolution Running Safety Secure Security Site Source Statistical Data Interpretation Therapeutic Transplantation U-Series Cooperative Agreements Validation Work beta cell replacement cell replacement therapy data exchange data registry experience flexibility follow-up health assessment meetings multidisciplinary new technology posters programs quality assurance response success transplant registry

项目摘要

PROJECT SUMMARY This application, in response to RFA-DK-21-013, describes a comprehensive Data and Statistical Coordinating Center (DSCC) for the Collaborative Islet Transplant Registry (CITR) for 2022-2027. Continuing from 2017-2021 as the CITR-DSCC, Emmes continues to collaborate with the NIDDK Program Office, the Oversight Committee, and the CITR investigators to support the established CITR Registry. The registry includes allogeneic and autologous pancreatic islet transplantation, as well as any other beta cell replacement therapies that should be followed for efficacy and safety in the resolution of refractory glycemic lability marked by severe hypoglycemic episodes in persons with Type 1 diabetes or lacking pancreatic islets for any reason including therapeutic pancreatectomy or any loss of islet cell function. For more details, please see the Specific Aims section.

项目摘要本申请作为对RFA-DK-21-013的响应，描述了一个全面的数据和统计协调 2022-2027年合作胰岛移植登记中心（CITR）。2017-2021年持续作为CITR-DSCC，埃姆斯继续与NIDDK计划办公室、监督委员会和CITR调查员，以支持已建立的CITR登记处。登记处包括同种异体和自体胰岛移植，以及任何其他β细胞替代疗法，应该是随访了以重度低血糖为标志的难治性血糖不稳定的疗效和安全性 1型糖尿病患者或因任何原因（包括治疗性）缺乏胰岛的患者胰腺切除术或任何胰岛细胞功能丧失。更多详情，请参阅具体目标部分。